Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,961 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastric Clear all
Completed Phase 1 Interventional

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

NCT00019435
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated No phase listed Observational

LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm

NCT04695171
View directory record Official record
Conditions
Hiatal Hernia Large, Gastro Esophageal Reflux, Hiatal Hernia, Hiatal Hernia, Paraesophageal, Reflux, Gastroesophageal, Reflux Acid
Interventions
LINX Reflux Management System, Fundoplication
Device · Procedure
Lead sponsor
Foregut Research Foundation
Other
Eligibility
21 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Lone Tree, Colorado • Coral Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

NCT02333604
View directory record Official record
Conditions
Neoplasms, Cancer, Caregiver
Interventions
Not listed
Lead sponsor
Cancer Support Community, Research and Training Institute, Philadelphia
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting No phase listed Observational

Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry

NCT04494048
View directory record Official record
Conditions
Obesity, Weight Loss, Gastro Esophageal Reflux, Bariatric Surgery Candidate
Interventions
Endoscopic Bariatric Therapies
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
9,999 participants
Timeline
2016 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Not listed Phase 2 Interventional

Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors

NCT00178698
View directory record Official record
Conditions
Neuroendocrine Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer
Interventions
thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

NCT00397904
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cetuximab, cisplatin, irinotecan hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 23, 2026, 8:59 PM EDT
Enrolling by invitation No phase listed Observational

Physiologic and Functional Adaptations of Insulin Sensitive Tissues

NCT03407833
View directory record Official record
Conditions
Diabetes, Insulin Resistance, Obesity, Bariatric Surgery Candidate, Roux-en-y Gastric Bypass, Liver Diseases
Interventions
Endoscopy biopsy, Surgical biopsy, Mixed-meal tolerance test, Excised Liver Tissue Sampling
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 23, 2026, 8:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Not yet recruiting Phase 2 Interventional

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

NCT07059611
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
RP2, 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Pegfilgrastim, Filgrastim, Surgical Resection of Primary Tumor
Biological · Combination Product · Drug + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

Embryonal Tumor With Multilayered Rosettes

NCT06861244
View directory record Official record
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

NCT00683787
View directory record Official record
Conditions
Gastric Cancer
Interventions
docetaxel, vandetanib
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department

NCT01376414
View directory record Official record
Conditions
Gastritis, Peptic Ulcer, Peptic Ulcer Perforation, Stomach Ulcer
Interventions
Urea Breath Test (UBT) for H. pylori infection
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation

NCT01781104
View directory record Official record
Conditions
Constipation
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated No phase listed Observational

Gastric Accommodation and Gastroesophageal Reflux

NCT01078064
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

NCT02232308
View directory record Official record
Conditions
Gastroparesis
Interventions
Nizatidine, Lisinopril, Placebo
Drug
Lead sponsor
Adil Bharucha
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

NCT04614974
View directory record Official record
Conditions
Laryngomalacia, Gastro Esophageal Reflux
Interventions
Famotidine, Speech Language Therapy
Drug · Other
Lead sponsor
Reema Padia
Other
Eligibility
0 Months to 6 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 23, 2026, 8:59 PM EDT
Completed No phase listed Observational Results available

Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

NCT05886218
View directory record Official record
Conditions
Sugammadex
Interventions
Quantitative Neuromuscular Function Monitoring
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
183 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

NCT06003985
View directory record Official record
Conditions
Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions
Gastric Ultrasound Exam
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 99 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

NCT07488676
View directory record Official record
Conditions
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
ASP546C
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK962040 Drug-drug Interaction Study With Ketoconazole

NCT01039974
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040, Ketoconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 23, 2026, 8:59 PM EDT
Active, not recruiting Not applicable Interventional

Combined Role of Gastric Peroral Endoscopic Myotomy and Gastric Electrical Stimulator

NCT07526935
View directory record Official record
Conditions
Gastroparesis
Interventions
GES + Upper endoscopy, GES on + Upper endscopy, GES off + G-POEM, GES on + G-POEM
Device · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

NCT04117958
View directory record Official record
Conditions
MUC17-positive Solid Tumors
Interventions
AMG 199
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Duarte, California • Orange, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting Not applicable Interventional

Autonomic Neural Blockade in Bariatric Surgery

NCT07104825
View directory record Official record
Conditions
Bariatric Surgery Candidate, Pain, Postoperative, Nausea and Vomiting, Postoperative, Opioid Use
Interventions
Intraoperative autonomic neural blockade (ANB), Laparoscopic Standard of Care Abdominal Wall Block
Procedure
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 8:59 PM EDT